spacer
home > ict > spring 2008 > solid supply
PUBLICATIONS
International Clinical Trials

Solid Supply

Chris Tierney at DHL Exel Supply Chain considers the need for consolidation of global clinical trial supply networks alongside the twin drivers of cost reduction and service enhancement within this increasingly competitive industry

In the last decade, there has been considerable consolidation within the pharmaceutical industry across the globe. This has, in the main, been precipitated by an overall theme of rationalisation, whereby mergers and acquisitions have reduced the number of large and mid-sized pharmaceutical companies with a pharmaceutical development focus. At the same time, the geographic scope and the scale of clinical studies has enjoyed a marked increase, with the pursuit of patient populations leading sponsors to emerging markets such as the Far East, Middle East and South America.

The environment in which today’s organisations operate has been characterised by a series of conflicting demands driving a focus on increasing the value of every R&D dollar invested. This is manifested as globalisation, a renewed vigour on cost reduction within R&D budgets and competition for target principal investigators and their patient populations.

READING TRENDS

For the supply chain, the impact of this shift is many-fold. The acquisition trend has led to a raft of varied products, many of which have become, or are heading towards, obsolescence. Companies are increasingly operating with multiple systems and from multiple facilities (both owned and third party) across the world. The result is a lack of visibility in terms of where products are at any given time, and a need to analyse the delivery of clinical supplies to investigators in order to avoid duplication of cost and resources.

Consequently, the more successful companies have, or are undergoing, a strategic business evaluation that takes a fresh look at the existing clinical trials logistics network and provides a proposition that, in the main, moves away from the legacy affiliate networks and introduces a strategic redesign that enables the creation of a supply chain for 2012 and beyond. This will allow the most agile organisations to capitalise quickly on accessing a wide range of diverse patient populations and focusing recruitment on lower cost geographies (at the expense of the more mature Western populations).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Tierney graduated in 1995 with a BSc in Medical Biochemistry and shortly after joined Exel’s international management training scheme. He has worked in operations, strategic marketing and product development. In 2003, Chris completed his MBA. Chris’s current role is Business Development Manager for DHL Healthcare, and he has responsibility for global sales and the strategic development of the clinical trials logistics offerings
spacer
Chris Tierney
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement